Pharma Journalist -

Lyndra, Inc. announced the closing of a $23 Million Series A financing, led by Polaris Partners, with participation from Quark Venture and GF Securities, Yonghua Capital, Healthlink…
Read More...

Icon Bioscience Inc. (IBI), a specialty biopharmaceutical company focused on utilizing its Verisome drug-delivery platform to develop unique intraocular eye-care therapeutics announced…
Read More...

BMS (Bristol-Myers Squibb) announced that it has entered into two separate agreements with Biogen and Roche to license to compounds. BMS-986168, an anti-eTau compound in development…
Read More...

Transgene (Paris:TNG), a company that designs and develops viral-based immunotherapies announces that the first patient with soft tissue sarcoma (STS) has been treated in the Phase 2…
Read More...

Through our collaborations with regulatory agencies, and partnerships with major global nonprofits, we, at Certara, continuously strive to provide up-to-date solutions to help…
Read More...

1CellBiO Inc announced today a research collaboration with UCB to validate and deploy the inDrop™ high throughput single cell RNA sequencing platform in order to better understand the…
Read More...

KYORIN Holdings, Inc. announced today that its wholly owned subsidiary, KYORIN Pharmaceutical Co., Ltd., has entered into a license agreement with Merck & Co., Inc., Kenilworth,…
Read More...

Neurocrine Biosciences’ Ingrezza (valbenazine) capsules has been approved by US FDA (food and Drug Administration) for treatment of tardive dyskinesia (TD). TD is characterised by…
Read More...

OncoMed Pharmaceuticals’ demcizumab (anti-DLL4, OMP-21M18) has failed to meet its primary endpoint in the Phase 2 YOSEMITE clinical trial in combination with Abraxane (paclitaxel…
Read More...

The U.S. Food and Drug Administration today approved supplemental applications for Sovaldi (sofosbuvir) and Harvoni (ledipasvir and sofosbuvir) to treat hepatitis C virus (HCV) in…
Read More...